The San Francisco incubator has officially begun human clinical trials for three of its therapeutic development programs.
Live Poll
Do you trust that venture-biotech company models successfully deliver new medical treatments to patients?
October 20, 2026
Epicrispr Biotechnologies Appoints Enoch Kariuki to BoardThe San Francisco-based biotech firm adds the experienced executive as it advances its lead muscular dystrophy program.
October 16, 2026
Tuscany Renews Biotech Partnership in San FranciscoThe region aims to leverage Silicon Valley expertise to advance its local technology ecosystem.
October 14, 2026
Siren Biotechnology Appointed Peter Bross to Advisory BoardThe San Francisco-based firm recruited the former FDA oncology branch chief to guide its clinical program.
October 7, 2026
Researchers Reshaped Nanopores With Designed ProteinsScientists at UCSF and Oxford Nanopore Technologies installed a synthetic protein into a pore to modify its inner lumen.
October 6, 2026
Multiply Labs Raised $75 Million in Series B FundingThe San Francisco biotech firm will use the new capital to scale its automated gene therapy manufacturing robots.
September 29, 2026
Longevica Therapeutics Formed Scientific Advisory BoardThe San Francisco biotech firm appointed a board to oversee its pivot toward clinical development.
September 28, 2026
UCSF Benioff Named First WASKYRA Treatment CenterThe hospital is the first site in the U.S. authorized to administer the gene therapy for Wiskott-Aldrich Syndrome.
September 18, 2026
Electra Therapeutics Completed Initial Public OfferingThe San Francisco-based biotech firm successfully raised $350 million in an upsized offering.
